Enhertu recommended for approval in the EU by CHMP for patients with HER2-low metastatic breast cancer January 4, 2023
Carrick Therapeutics and The Menarini Group to Evaluate Samuraciclib and Elacestrant Combination December 20, 2022
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs December 19, 2022
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer December 13, 2022
First Patient Dosed in Ph 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer December 13, 2022
ARV-471 Achieves a CBR of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Ph 2 Expansion Trial (VERITAC) November 30, 2022
ENHERTU® Approved in Japan for Patients with Previously Treated HER2 Positive Metastatic Breast Cancer November 30, 2022
MARIO-3 Updates reported in Patients with 1L mTNBC Suggesting Potential Long-Term Patient Benefit of Eganelisib November 23, 2022
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline November 16, 2022
Initial Results From Ph 2 Trial Demonstrate Potential Of Trilaciclib To Reduce Adverse Events Related To An ADC November 16, 2022
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Ph 2 trial in advanced ER-positive breast cancer November 4, 2022
Capivasertib plus Faslodex significantly improved PFS vs. Faslodex in CAPItello-291 Ph 3 trial November 4, 2022
FAILED TRIAL: Ph 2 AMEERA-3 trial of amcenestrant in ER+/HER2- advanced or metastatic breast cancer did not meet primary endpoint of improving PFS November 4, 2022
Ph I part of the clinical trial of Bria-IMT™, in combination with retifanlimab, in advanced breast cancer completed October 26, 2022
Enrollment Completed in Global Multi-Center Ph 3 Clinical Trial of Trilaciclib in Patients with mTNBC October 19, 2022
U.S. FDA Accepts For Priority Review Supplemental BLA For Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer October 19, 2022
FDA approves first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU October 12, 2022
KEYTRUDA® Receives Four New Approvals in Japan, Including in High-Risk Early-Stage TNBC October 5, 2022
FDA approved Lytgobi (futibatinib) for adults with advanced intrahepatic cholangiocarcinoma (iCCA) who have FGFR2 gene fusions or other rearrangements October 5, 2022
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib September 28, 2022
Trodelvy® Significantly Improved OS In Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients In TROPiCS-02 Study September 13, 2022
Kisqali® Adds One More Year Of Survival Benefit For Broadest Set Of Patients, Including Those With Aggressive HR+/HER2- Advanced Breast Cancer September 13, 2022
Enhertu continues to demonstrate clinically meaningful tumour response in patients with HER2-mutant mNSCLC September 13, 2022
